IThis listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented)Compounds of the formula I



I

in which

Het denotes a mono- or bicyclic aromatic heterocyclic radical having from 1 to 3 N, O and/or S atoms which is mono- or disubstituted by Hal,

R^1 denotes A, which may be mono-, di- or trisubstituted by $S(O)_mA$, Ph, NH_2, NHA, NA_2, OH, OA, $PO(OA)_2$, ethynyl, vinyl or $O(CH_2)_nPh$,

R^2 denotes H, Hal or A,

R^3 denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,

A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms,

Ph denotes phenyl,

Hal denotes F, Cl, Br or I,

n denotes 1, 2, 3, 4, 5 or 6,

m denotes 0, 1 or 2,

and pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

2. (Previously Presented)Compounds according to Claim 1, in which

R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA,

or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

3. (Previously Presented)Compounds according to Claim 1, in which

R^3 denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

4. (Previously Presented)Compounds according to claim 1, in which

R^2 denotes H, methyl or F,

or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to claim 1, in which

Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl

or oxazolyl, each of which is mono- or disubstituted by Hal,

and pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

6. (Previously Presented)Compounds according to claim 1, in which

Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or disubstituted by Hal,

R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA,

R^2 denotes H, Hal or A,

R^3 denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms,

Ph denotes phenyl,

Hal denotes F, Cl, Br or I,

n denotes 1, 2, 3, 4, 5 or 6,

m denotes 0, 1 or 2,

or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

7. (Previously Presented)Compounds according to Claim 1 of the formula

1-(5-chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-propylsemicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-(prop-2-ynyl)semicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,

1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,

1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-benzylsemicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,

1-(5-bromothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 or pharmaceutically usable ~~comprising~~ salts or stereoisomers thereof, comprising reacting

a) a compound of the formula II



II

in which

R^1, R^2 and R^3 have the meaning indicated in Claim 1,

with a compound of the formula III

Het-CO-L III

in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

Het has the meaning indicated in Claim 1,

and/or converting

a base or acid of the formula I into one of its salts.

9. (Previously Presented) A method of inhibiting coagulation factor Xa,

comprising administering to a host in need thereof, a compound of the formula I according to claim 1.

10. (Previously Presented)A method of inhibiting coagulation factor VIIa, comprising administering to a host in need thereof, a compound of the formula I according to claim 1.

11. (Previously Presented) a pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios, andpharmaceutically acceptable excipients and/or adjuvants.

12. (Previously Presented)A pharmaceutical composition according to claim 11, further comprising at least one further medicament active ingredient.

13. (Canceled).

14. (Previously Presented)Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

15. (Canceled).

16. (Canceled).

17. (Previously Presented) A method for the treatment of thrombosis, comprising

administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.